Table 2. Studies including at least 20... | American Society of Hematology

Table 2.

Studies including at least 20 MPN patients on DOAC treatment for usual site VTE

Reference	Study population	N on DOAC	N on rivar	N on apix	N on edox	N on dabig	Overall thrombotic recurrence	VTE recurrence	Major bleeding	Median follow-up (years)
Ianotto et al²⁵	PV/ET receiving DOAC for AF or VTE	25^*	16	9	—	—	4% (1 stroke)	0	12%	2.1
Curto-Garcia et al²⁶	PV/ET/PMF/MDS-MPN receiving DOAC for VTE	32	17	14	1	0	3% (1 mesenteric ischemia)	0	0%	2.1
Serrao et al²⁷	PV/ET/PMF receiving DOAC for AF or VTE	71^†	26	21	14	10	0%	—	0%	1
Barbui et al²⁸	PV/ET/PMF receiving DOAC for AF or VTE	442^‡	187	157	48	50	4.9% (2.1% pt-y) (AF) 9.2% (4.5% pt-y) (VTE)	1.5% (0.6% pt-y) (AF) 7.1% (3.4% pt-y) (VTE)	6.9% (3.0 pt-y) (AF) 5.0% (2.3% pt-y) (VTE)	1.7

Reference	Study population	N on DOAC	N on rivar	N on apix	N on edox	N on dabig	Overall thrombotic recurrence	VTE recurrence	Major bleeding	Median follow-up (years)
Ianotto et al²⁵	PV/ET receiving DOAC for AF or VTE	25^*	16	9	—	—	4% (1 stroke)	0	12%	2.1
Curto-Garcia et al²⁶	PV/ET/PMF/MDS-MPN receiving DOAC for VTE	32	17	14	1	0	3% (1 mesenteric ischemia)	0	0%	2.1
Serrao et al²⁷	PV/ET/PMF receiving DOAC for AF or VTE	71^†	26	21	14	10	0%	—	0%	1
Barbui et al²⁸	PV/ET/PMF receiving DOAC for AF or VTE	442^‡	187	157	48	50	4.9% (2.1% pt-y) (AF) 9.2% (4.5% pt-y) (VTE)	1.5% (0.6% pt-y) (AF) 7.1% (3.4% pt-y) (VTE)	6.9% (3.0 pt-y) (AF) 5.0% (2.3% pt-y) (VTE)	1.7

13 patients receiving DOAC for AF, 4 for AF and stroke, and 8 for VTE.

35 patients receiving DOAC for AF; 36 for VTE.

203 patients receiving DOAC for AF; 239 for VTE.

Apix, apixaban; dabig, dabigatran; edox, edoxaban; rivar, rivaroxaban.